Principles for Designing an Optimal MRNA Lipid Nanoparticle Vaccine

Overview

Journal Curr Opin Biotechnol

Publisher Elsevier

Specialty Biotechnology

Date 2021 Oct 29

PMID 34715546

Citations 92

Authors

Edo Kon

Uri Elia

Dan Peer

Affiliations

Soon will be listed here.

Abstract

mRNA Lipid nanoparticles (LNPs) have recently been propelled onto the center stage of therapeutic platforms due to the success of the SARS-CoV-2 mRNA LNP vaccines (mRNA-1273 and BNT162b2), with billions of mRNA vaccine doses already shipped worldwide. While mRNA vaccines seem like an overnight success to some, they are in fact a result of decades of scientific research. The advantage of mRNA-LNP vaccines lies in the modularity of the platform and the rapid manufacturing capabilities. However, there is a multitude of choices to be made when designing an optimal mRNA-LNP vaccine regarding efficacy, stability and toxicity. Herein, we provide a brief on what we consider to be the most important aspects to cover when designing mRNA-LNPs from what is currently known and how to optimize them. Lastly, we give our perspective on which of these aspects is most crucial and what we believe are the next steps required to advance the field.

Citing Articles

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.

Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B Signal Transduct Target Ther. 2025; 10(1):73.

PMID: 40059188 PMC: 11891339. DOI: 10.1038/s41392-024-02112-8.

Ionizable Lipids with Optimized Linkers Enable Lung-Specific, Lipid Nanoparticle-Mediated mRNA Delivery for Treatment of Metastatic Lung Tumors.

Somu Naidu G, Rampado R, Sharma P, Ezra A, Kundoor G, Breier D ACS Nano. 2025; 19(6):6571-6587.

PMID: 39912611 PMC: 11841047. DOI: 10.1021/acsnano.4c18636.

Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery.

Xu Y, Gong F, Golubovic A, Strilchuk A, Chen J, Zhou M Proc Natl Acad Sci U S A. 2025; 122(5):e2409572122.

PMID: 39883839 PMC: 11804478. DOI: 10.1073/pnas.2409572122.

Research progress of mosquito-borne virus mRNA vaccines.

Sun N, Su Z, Zheng X Mol Ther Methods Clin Dev. 2025; 33(1):101398.

PMID: 39834558 PMC: 11743085. DOI: 10.1016/j.omtm.2024.101398.

High mRNA Expression of 24 Dehydrocholesterol Reductase (DHCR24) in the Treatment of Doxorubicin-Induced Heart Failure in Rats.

Zhang R, Peng S, Zhang X, Huang Z, Pan X Int J Mol Sci. 2025; 26(1.

PMID: 39796168 PMC: 11719971. DOI: 10.3390/ijms26010312.

References

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

Lima S, Chipman L, Nicholson A, Chen Y, Yee B, Yeo G . Short poly(A) tails are a conserved feature of highly expressed genes. Nat Struct Mol Biol. 2017; 24(12):1057-1063. PMC: 5877826. DOI: 10.1038/nsmb.3499. View

Sato Y, Hashiba K, Sasaki K, Maeki M, Tokeshi M, Harashima H . Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo. J Control Release. 2019; 295:140-152. DOI: 10.1016/j.jconrel.2019.01.001. View

Orlandini von Niessen A, Poleganov M, Rechner C, Plaschke A, Kranz L, Fesser S . Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. Mol Ther. 2019; 27(4):824-836. PMC: 6453560. DOI: 10.1016/j.ymthe.2018.12.011. View

Ball R, Bajaj P, Whitehead K . Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization. Int J Nanomedicine. 2017; 12:305-315. PMC: 5221800. DOI: 10.2147/IJN.S123062. View

Schoenmaker L, Witzigmann D, Kulkarni J, Verbeke R, Kersten G, Jiskoot W . mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021; 601:120586. PMC: 8032477. DOI: 10.1016/j.ijpharm.2021.120586. View

Asrani K, Farelli J, Stahley M, Miller R, Cheng C, Subramanian R . Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol. 2018; 15(6):756-762. PMC: 6152433. DOI: 10.1080/15476286.2018.1450054. View

De Beuckelaer A, Pollard C, Van Lint S, Roose K, Van Hoecke L, Naessens T . Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses. Mol Ther. 2016; 24(11):2012-2020. PMC: 5154477. DOI: 10.1038/mt.2016.161. View

10.

Elia U, Ramishetti S, Rosenfeld R, Dammes N, Bar-Haim E, Somu Naidu G . Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered Lipid Nanoparticles. ACS Nano. 2021; 15(6):9627-9637. DOI: 10.1021/acsnano.0c10180. View

11.

Granados-Riveron J, Aquino-Jarquin G . Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Biomed Pharmacother. 2021; 142:111953. PMC: 8299225. DOI: 10.1016/j.biopha.2021.111953. View

12.

Zhao P, Hou X, Yan J, Du S, Xue Y, Li W . Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioact Mater. 2020; 5(2):358-363. PMC: 7078456. DOI: 10.1016/j.bioactmat.2020.03.001. View

13.

Kudla G, Lipinski L, Caffin F, Helwak A, Zylicz M . High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 2006; 4(6):e180. PMC: 1463026. DOI: 10.1371/journal.pbio.0040180. View

14.

Corbett K, Edwards D, Leist S, Abiona O, Boyoglu-Barnum S, Gillespie R . SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020; 586(7830):567-571. PMC: 7581537. DOI: 10.1038/s41586-020-2622-0. View

15.

Buschmann M, Carrasco M, Alishetty S, Paige M, Alameh M, Weissman D . Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines (Basel). 2021; 9(1). PMC: 7836001. DOI: 10.3390/vaccines9010065. View

16.

Hassett K, Benenato K, Jacquinet E, Lee A, Woods A, Yuzhakov O . Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol Ther Nucleic Acids. 2019; 15:1-11. PMC: 6383180. DOI: 10.1016/j.omtn.2019.01.013. View

17.

Maier M, Jayaraman M, Matsuda S, Liu J, Barros S, Querbes W . Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013; 21(8):1570-8. PMC: 3734658. DOI: 10.1038/mt.2013.124. View

18.

Hou X, Zaks T, Langer R, Dong Y . Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6(12):1078-1094. PMC: 8353930. DOI: 10.1038/s41578-021-00358-0. View

19.

Tatematsu M, Funami K, Seya T, Matsumoto M . Extracellular RNA Sensing by Pattern Recognition Receptors. J Innate Immun. 2018; 10(5-6):398-406. PMC: 6784046. DOI: 10.1159/000494034. View

20.

Kremsner P, Ahuad Guerrero R, Arana-Arri E, Aroca Martinez G, Bonten M, Chandler R . Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2021; 22(3):329-340. PMC: 8610426. DOI: 10.1016/S1473-3099(21)00677-0. View